



Axiron® (testosterone) – First-time generic

- Perrigo and Prasco have received FDA approval for their generic versions of Eli Lilly's [Axiron \(testosterone\)](#) topical solution.
 - Perrigo's generic is [AT-rated](#) to brand Axiron. Prasco's product is an authorized generic.
- Axiron is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone:
 - **Primary hypogonadism (congenital or acquired):** testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals.
 - **Hypogonadotropic hypogonadism (congenital or acquired):** gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation.
- U.S. annual [sales](#) for Axiron were approximately \$254 million for the 12 months ending in January 2017.
- The launch plans for Perrigo's and Prasco's generic Axiron are pending.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.